Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


Phase III FALCON study of bardoxolone in patients with autosomal dominant polycystic kidney disease is paused.- Reata Pharma

Written by | 6 Apr 2020 | COVID-19

Reata Pharmaceuticals, Inc. provided an update on the impact of the COVID-19 pandemic on its clinical programs, drug supply chain, and business operations The Company announced measures it is taking to protect the health and safety of patients and health care workers involved in ongoing clinical studies of its investigational medicines, as well as its employees and collaborators.

The Company has temporarily paused enrollment of new patients in the Phase III FALCON trial of bardoxolone in patients with autosomal dominant polycystic kidney disease (ADPKD). Patients already enrolled in FALCON will continue in the study. The Company is implementing procedures for the conduct of FALCON that are similar to those being used in CARDINAL to ensure continued access to study drug and appropriate safety monitoring. The Company plans to resume patient screening and enrollment as soon as the situation permits.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.